A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
Study of Paclitaxel With and Without Nivolumab and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT2905
U.S. Govt. ID: NCT04339738
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (cancer) in patients who have either received paclitaxel or similar chemotherapy previously, or whose cancer has grown previously while getting paclitaxel chemotherapy on this study. The chemotherapy drugs, paclitaxel and cabozantinib, work to prevent cells from growing. Nivolumab is a drug that works through your bodys immune system to help the immune system act against cancer cells. Nivolumab has been studied and found to shrink tumors in some people with cancer. Researchers hope to learn if the combination of nivolumab and chemotherapy could shrink your type of tumor, and possibly prevent it from coming back.
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with angiosarcoma? Yes No
Are you willing to come to the clinic once per week for chemotherapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162